CMFRI earns patent for anti-diabetic nutraceutical

CadalminTM ADe is an anti-diabetic nutraceutical, which is effective to combat type-2 diabetes

A patent has been granted to Kochi based Central Marine Fisheries Research Institute (CMFRI) for an invention entitled A process to prepare antidiabetic concentrates from seaweeds and a product thereof (Patent Number 346531) for the term of 20 years from the 19^th day of October 2015 in accordance with the provisions of the Patents Act, 1970. 

Cadalmin^TM ADe is an anti-diabetic nutraceutical, which is effective to combat type-2 diabetes. It contains 100% natural marine bioactive ingredients extracted from selected seaweeds.

The bioactive ingredients in Cadalmin^TM ADe competitively inhibit dipeptidyl peptidase-IV and tyrosine phosphatase 1B. The active ingredients of the product decreases production of various mediators responsible for inducing type-2 diabetes, and interfere with the release of simple sugars from the gut, which reduces postprandial hyperglycemia thereby hindering the occurrence of type-2 diabetes.

Cadalmin^TM ADe has no side effects as proved from the long-term toxicity studies. The active ingredients purified and concentrated; a total of 350 mg active ingredients in the product are packed in plant-based capsules (cellulose-based hypermelose) to meet the dietary needs of vegetarians.

The technology has been transfered to Pioneer Pharmaceuticals Limited in Kochi for commercial production and marketing.